Patents by Inventor Manuel Zancanella

Manuel Zancanella has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BRIDGED BICYCLIC KALLIKREIN INHIBITORS
    Publication number: 20180194780
    Abstract: Provided herein are kallikrein modulating compounds, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Application
    Filed: November 8, 2017
    Publication date: July 12, 2018
    Inventors: Zhe Li, Manuel Zancanella, Chul Yu, Lina Q. Setti, Hing Sham, Qing Xu, Calvin W. Yee, Ming Yu
  • Bridged bicyclic kallikrein inhibitors
    Patent number: 9815853
    Abstract: Provided herein are kallikrein modulating compounds, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: November 14, 2017
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Zhe Li, Manuel Zancanella, Chul Yu, Lina Setti, Hing Sham, Qing Xu, Calvin Yee, Ming Yu
  • COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
    Publication number: 20170088560
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: December 12, 2016
    Publication date: March 30, 2017
    Applicant: Amgen Inc.
    Inventors: Sean P. BROWN, Yunxiao LI, Mike Elias LIZARZABURU, Brian S. LUCAS, Nick A. PARAS, Joshua TAYGERLY, Marc VIMOLRATANA, Xianghong WANG, Ming YU, Manuel ZANCANELLA, Liusheng ZHU, Ana GONZALEZ BUENROSTRO, Zhihong LI
  • Compounds that inhibit MCL-1 protein
    Patent number: 9562061
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: February 7, 2017
    Assignee: Amgen Inc.
    Inventors: Sean P. Brown, Yunxiao Li, Joshua Taygerly, Marc Vimolratana, Xianghong Wang, Manuel Zancanella
  • BRIDGED BICYCLIC KALLIKREIN INHIBITORS
    Publication number: 20160362427
    Abstract: Provided herein are kallikrein modulating compounds, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Application
    Filed: June 9, 2016
    Publication date: December 15, 2016
    Inventors: Zhe Li, Manuel Zancanella, Chul Yu, Lina Setti, Hing Sham, Qing Xu, Calvin Yee, Ming Yu
  • COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
    Publication number: 20160068545
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: August 28, 2015
    Publication date: March 10, 2016
    Applicant: AMGEN INC.
    Inventors: Sean P. BROWN, Yunxiao LI, Mike Elias LIZARZABURU, Brian S. Lucas, Nick A. Paras, Joshua Taygerly, Marc VIMOLRATANA, Xianghong Wang, Ming Yu, Manuel ZANCANELLA, Liusheng Zhu, Ana GONZALEZ BUENROSTRO, Zhihong LI
  • Beta-lactone compounds
    Patent number: 8258321
    Abstract: The present invention provides compounds having the general structure A, or a pharmaceutically acceptable derivatives thereof: wherein R is an alkyl group, and R1 comprises at least one moiety selected from a group consisting of an alkyl, an alkenyl, an aryl, a heterocycle, hydroxyl, ester, amido, aldehyde, and a halogen.
    Type: Grant
    Filed: October 30, 2008
    Date of Patent: September 4, 2012
    Assignees: Burnham Institute for Medical Research, The Texas A&M University System
    Inventors: Jeffrey W. Smith, Daniel Romo, Gil Ma, Manuel Zancanella
  • BETA-LACTONE COMPOUNDS
    Publication number: 20090124681
    Abstract: The present invention provides compounds having the general structure A, or a pharmaceutically acceptable derivatives thereof: wherein R is an alkyl group, and R1 comprises at least one moiety selected from a group consisting of an alkyl, an alkenyl, an aryl, a heterocycle, hydroxyl, ester, amido, aldehyde, and a halogen.
    Type: Application
    Filed: October 30, 2008
    Publication date: May 14, 2009
    Applicants: Burnham Institute for Medical Research, The Texas A & M University System
    Inventors: Jeffrey W. Smith, Daniel Romo, Gil Ma, Manuel Zancanella